Neuroimmunomodulation · 2019
Clinical Heterogeneity in Patients with Glutamate Decarboxylase Antibody.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Jiehong, Li Huilu, Zhou Ruisi, Huang Wenyao, Lin Wenhui, Chen Ting, Long Youming
Аннотация
OBJECTIVE: To explore the diversity and clinical features of anti-glutamate decarboxylase (GAD) antibody-associated neurological diseases.
METHODS: Clinical data of a series of 5 patients positive for anti-GAD antibodies were retrospectively analyzed.
RESULTS: All 5 patients were female, with a median age of 41.5 years (range 19-60 years). Their neurological symptoms included stiff-person syndrome (SPS), encephalitis, myelitis, cramp, visual loss, and paresthesia. Three patients (60%) were diagnosed with tumors, 2 cases of thymic tumor and 1 of breast cancer. On immunohistochemistry for tumor pathology, expression of GAD65 was found only in 1 patient. Four patients (80%) had abnormal brain MRI findings. All patients received immunotherapy and improved significantly after treatment, but 4 (80%) then experienced a relapse.
CONCLUSIONS: Neurological manifestations in anti-GAD-positive patients are diverse and include SPS, encephalitis, myelitis, cramp, visual loss, and paresthesia.
METHODS: Clinical data of a series of 5 patients positive for anti-GAD antibodies were retrospectively analyzed.
RESULTS: All 5 patients were female, with a median age of 41.5 years (range 19-60 years). Their neurological symptoms included stiff-person syndrome (SPS), encephalitis, myelitis, cramp, visual loss, and paresthesia. Three patients (60%) were diagnosed with tumors, 2 cases of thymic tumor and 1 of breast cancer. On immunohistochemistry for tumor pathology, expression of GAD65 was found only in 1 patient. Four patients (80%) had abnormal brain MRI findings. All patients received immunotherapy and improved significantly after treatment, but 4 (80%) then experienced a relapse.
CONCLUSIONS: Neurological manifestations in anti-GAD-positive patients are diverse and include SPS, encephalitis, myelitis, cramp, visual loss, and paresthesia.
Предметные рубрики MeSH
AdultAutoantibodiesAutoimmune Diseases of the Nervous SystemBrainBreast NeoplasmsEncephalitisFemaleGlutamate DecarboxylaseHumansMagnetic Resonance ImagingMiddle AgedMuscle CrampMyelitisParaneoplastic Syndromes, Nervous SystemParesthesiaRecurrenceRetrospective StudiesStiff-Person SyndromeThymus NeoplasmsVision DisordersYoung Adult